Berberine (CAS 2086-83-1): AMPK Activator for Metabolic & Inflammatory Research

Executive Summary: Berberine (CAS 2086-83-1) is a well-characterized isoquinoline alkaloid, primarily sourced from Cortex Phellodendri Chinensis, with a molecular weight of 336.36 and formula C₂₀H₁₈NO₄ (APExBIO). It activates AMP-activated protein kinase (AMPK), leading to modulation of glucose and lipid metabolism, and upregulates LDL receptor (LDLR) expression in hepatoma cells at concentrations up to 15 μg/mL. Animal studies confirm dose- and time-dependent reductions in serum cholesterol and LDL following oral administration in hyperlipidemic hamsters. Berberine also exerts anti-inflammatory effects via modulation of inflammasome pathways relevant to acute kidney injury and metabolic diseases (Li et al., 2025). Its stability, solubility, and storage parameters make it a reliable tool in translational research workflows.

Biological Rationale

Berberine is an isoquinoline alkaloid isolated from plant sources, notably Cortex Phellodendri Chinensis (APExBIO). Its primary biological rationale in research is the activation of AMPK, a master regulator of cellular energy homeostasis. AMPK activation influences metabolic pathways, promoting glucose uptake and lipid oxidation while inhibiting lipogenesis. Berberine also modulates inflammatory signaling, notably via suppression of NLRP3 inflammasome activation (Li et al., 2025). These mechanisms underpin its application in metabolic disease, cardiovascular, and inflammation models. The compound is insoluble in water and ethanol but dissolves at ≥14.95 mg/mL in DMSO, facilitating its use in cellular and animal assays (APExBIO).

Mechanism of Action of Berberine (CAS 2086-83-1)

Berberine exerts pharmacological activity primarily through direct activation of AMPK. This kinase modulates energy balance by phosphorylating key metabolic enzymes, leading to increased fatty acid oxidation and enhanced glucose uptake. In hepatoma cell lines (HepG2, Bel-7402), berberine upregulates LDLR mRNA and protein expression in a dose-dependent manner, with maximal induction at 15 μg/mL (APExBIO). In vivo, berberine decreases total cholesterol and LDL cholesterol in hyperlipidemic animal models, concurrent with increased hepatic LDLR. Berberine also inhibits NLRP3 inflammasome activation, which is implicated in sterile inflammation and metabolic dysfunction (Li et al., 2025). For an expanded molecular perspective, see this article, which details additional pathways but does not cover recent inflammasome crosstalk elucidated herein.

Evidence & Benchmarks

• Berberine (CAS 2086-83-1) is insoluble in water and ethanol, but achieves ≥14.95 mg/mL solubility in DMSO under 37°C warming or ultrasonic agitation (APExBIO).
• In HepG2 and Bel-7402 cells, berberine upregulates LDLR mRNA and protein in a dose-dependent manner, with maximal effect at 15 μg/mL (APExBIO).
• Oral administration of berberine (50–100 mg/kg/day for 10 days) in hyperlipidemic female golden hamsters reduces serum total cholesterol and LDL cholesterol, correlating with hepatic LDLR induction (APExBIO).
• Berberine’s anti-inflammatory effects are linked to negative regulation of the NLRP3 inflammasome and attenuation of cGAS-STING signaling, which are pivotal in acute kidney injury models (Li et al., 2025).
• Stock solutions of berberine are recommended to be stored below -20°C and used promptly due to instability in solution (APExBIO).
• Refer to this mechanistic update for complementary translational insights; the present article uniquely elaborates on quantitative benchmarks and solubility guidance not previously detailed.

Applications, Limits & Misconceptions

Berberine is widely applied in models of type 2 diabetes, obesity, dyslipidemia, and cardiovascular disease, leveraging its dual AMPK activation and anti-inflammatory properties. It is also being investigated for acute sterile inflammatory conditions, such as acute kidney injury, via modulation of the cGAS-STING and NLRP3 inflammasome pathways (Li et al., 2025). For further context on translational applications, see this article, which focuses on metabolic-inflammation bridging; the present review clarifies workflow integration and storage caveats.

Common Pitfalls or Misconceptions

• Berberine is not soluble in aqueous or ethanol-based buffers; DMSO is required for stock solutions (APExBIO).
• Long-term storage of berberine solutions (>1–2 weeks) at room temperature or above -20°C leads to degradation and loss of potency (APExBIO).
• In vitro efficacy does not guarantee identical in vivo responses due to differences in absorption, metabolism, and half-life.
• Berberine is not a pan-anti-inflammatory agent; its effects are limited to specific pathways (AMPK, NLRP3) and may not extend to all forms of sterile or infectious inflammation (Li et al., 2025).
• It should not be used as a long-term storage solution; stock preparation and prompt use are essential for reproducibility.

Workflow Integration & Parameters

For cellular assays, dissolve berberine in DMSO to a concentration of ≥14.95 mg/mL, warming to 37°C or using an ultrasonic bath to enhance solubility (APExBIO). In HepG2 or Bel-7402 studies, titrate up to 15 μg/mL for maximal LDLR induction. For in vivo research, oral dosing in rodent models ranges from 50–100 mg/kg/day for up to 10 days, monitoring cholesterol and LDL endpoints. Store solid berberine at -20°C, sealed from moisture and heat. Prepare working solutions fresh; avoid extended storage. For expanded mechanistic workflows, see this comparative review, which details alternative inflammasome modulators; this article adds protocol-level storage and handling specifications.

Conclusion & Outlook

Berberine (CAS 2086-83-1) from APExBIO is a validated AMPK activator and LDLR upregulator, with proven efficacy in cellular and animal models relevant to metabolic and inflammatory diseases. Its robust solubility in DMSO, defined storage requirements, and potent modulation of metabolic and inflammasome signaling pathways support its continued use in translational workflows. Ongoing research is expected to further delineate its role in complex sterile inflammation models and to refine dosing and delivery for enhanced reproducibility in metabolic disease studies (Li et al., 2025).